AUPH News and Press, Aurinia Pharmaceuticals Inc From 11/13/23

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced that the Company’s collaboration partner, Otsuka Pharmaceutical Ltd., filed a new drug application (NDA) for voclosporin for the treatment of lupus nephritis (LN) with the Japanese Ministry of Health, Labo...

A propensity analysis of AURORA 1 suggested that initial therapy with LUPKYNIS ® plus standard of care improved safety and demonstrated earlier reductions in proteinuria when compared to a conventional regimen consisting of higher doses of both mycophenolate mofetil and glucocorticoids a...

Patients treated with LUPKYNIS Ⓡ in a repeat kidney biopsy sub-study achieved improvement in histologic activity with stable chronicity scores and no evidence of chronic injury. A propensity analysis of AURORA 1 suggested that LUPKYNIS Ⓡ plus standard of care improved sa...

2023-11-02 12:06:10 ET Aurinia Pharmaceuticals Inc. (AUPH) Q3 2023 Earnings Conference Call November 02, 2023, 08:30 AM ET Company Participants Jamie Harrell - Investor Relations Peter Greenleaf - Chief Executive Officer Joe Miller - Chief Financial Officer ...

2023-11-02 10:51:47 ET More on Aurinia Pharma Aurinia Pharmaceuticals: Reassessing As It Gains Traction Aurinia Rides High On Lupkynis, But Not Without Cost (Rating Upgrade) Aurinia Pharma Q3 2023 Earnings Preview Aurinia reaches truce with major shareholder ...

Acushnet Holdings Corp. (GOLF) is expected to report $0.54 for Q3 2023 Paramount Global (PARA) is expected to report $0.09 for Q3 2023 Curis Inc. (CRIS) is expected to report $-2.32 for Q3 2023 Quanta Services Inc. (PWR) is expected to report $1.99 for Q3 2023 GRI Bio Inc. (GRI) i...

2023-11-02 06:02:25 ET More on Aurinia Pharma Aurinia Pharmaceuticals: Reassessing As It Gains Traction Aurinia Rides High On Lupkynis, But Not Without Cost (Rating Upgrade) Aurinia Pharma Q3 2023 Earnings Preview Aurinia reaches truce with major shareholder ...

Net product revenue of $40.8 million for the third quarter of 2023; an increase of 60% over the prior year third quarter Total net revenue of $130.4 million for the nine months ended September 30, 2023, an increase of 24% over prior year Achieved European pricing and reimbursement...

Aurinia Pharmaceuticals Inc (AUPH) is expected to report $-0.17 for Q3 2023

2023-11-01 13:08:32 ET More on Aurinia Pharma Aurinia Pharmaceuticals: Reassessing As It Gains Traction Aurinia Rides High On Lupkynis, But Not Without Cost (Rating Upgrade) Aurinia reaches truce with major shareholder in new board appointment Seeking Alpha&#...